Pharmaceutical Group of the European Union

Members Area
Banner
screenshot

Cancer Care

Community pharmacists’ traditionally contributes to the provision of pain treatment, special nutrition, and management of chemotherapy side-effects in cancer patients.

Moreover the past decade, increasing numbers of cancer patients have received treatment at day-case chemotherapy clinics. New chemotherapy regimens have been designed specifically for day-case administration. Moreover, the increasing use of ambulatory pumps means that, for example, a five-day course of 5-fluorouracil for colorectal cancer can de delivered at home. In addition, the availability of oral chemotherapy has increased.

Community pharmacists’ role in the provision of pain treatment, special nutrition, and management of chemotherapy side-effects is common. In the future, however, more cancer patients may be managed in the community due to the availability of oral chemotherapy medicines. Such developments imply however a good coordination between hospital and ambulatory care and good collaboration among the healthcare team. To support such interventions, community pharmacists’ knowledge of the disease and its treatment has to follow current developments and anticipate such possibility, which in some cases is already a reality. Switching form intravenous to oral chemotherapy may allow increased access to treatment and convenience for patients.

In this area PGEU is committed to

PGEU Statements on cancer care and other related documents:

The PGEU is a collaborating partner of a new EU funded project entitled CANCON (Development of a European Guide for Quality Improvement in Comprehensive Caner Control) and will be part of WP2 – dissemination. The PGEU attended the first CANCON Stakeholders meeting in Brussels on 6th June.

More information on http://cancercontrol.eu/